Key Highlights

● Nanobiotix traded at about $28.83 in a mid-morning snapshot on October 22.

● The figure is a snapshot rather than a closing price.

● The Nasdaq-listed shares are American depositary receipts of the French company.

● The S&P 500 health care sector hit a record high.

Shares of Nanobiotix (NASDAQ:NBTX) jumped on Thursday, October 22, 2026, trading at about $28.83 in a mid-morning snapshot of health care movers. The rally placed the stock among the notable gainers on the Nasdaq Composite on a day when the index fell sharply.

There was no fresh catalyst. Nanobiotix did not release clinical data, partnership news or financial results tied to the move.

The shares that trade on Nasdaq are American depositary receipts, which represent shares of the French company. ADR prices can respond to trading in the home market, currency moves and US investor sentiment.

A French biotech on the move

Nanobiotix is a French biotechnology company. It was one of several health care names on a list of mid-morning movers on Thursday, a list that featured several sharp moves among smaller drug developers.

Like many companies still developing their main product, Nanobiotix's stock often moves on expectations about trials and regulatory progress. Shares of such companies can swing sharply even without new information, as investors reposition ahead of expected milestones.

The figure cited for Thursday was a mid-morning snapshot rather than a closing price, so the size of the gain at the close may have differed.

Health care shines as tech sinks

Nanobiotix's rise fit loosely into a broader rotation toward health care. The S&P 500 health care sector hit a record high on Thursday, according to market data, as investors moved money out of technology. Consumer staples had their best day since April 2025, and utilities and financials also gained. About two of every three S&P 500 stocks rose, according to market reports.

The sector's strength came despite a heavy fall in Moderna (NASDAQ:MRNA). Its shares tumbled after data from a Phase 3 melanoma vaccine trial run with Merck (NYSE:MRK) appeared before its scheduled presentation. Full results are due Saturday at the ESMO conference in Madrid.

Technology was the clear loser. The Nasdaq Composite closed at 26,008.86, down 694.00 points, its steepest drop since June 5. The slide ended a seven-session winning streak and erased about $1 trillion in market value, according to market data. The Philadelphia Semiconductor Index had its biggest one-day drop since June 23.

A weaker day overseas

Global markets were also soft. Europe had its biggest drop in three weeks, according to market data, and France's CAC 40 fell. French 10-year government bond yields moved above those on US 10-year Treasuries for the first time since 2013, amid concerns about the country's finances and political unrest.

That backdrop makes the Nanobiotix rally more notable. A French company's US-listed shares rose even as its home market weakened, which suggests the move was driven by company-specific trading interest rather than broad market forces.

In the US, Treasuries rallied, sending the 10-year yield back below a closely watched threshold for the first time since September 22.

Nanobiotix Watches Clinical Updates and Friday Trading

Investors will look for any update from Nanobiotix on its clinical programs, along with trading in its shares on Friday. Health care investors will also follow Saturday's full Moderna and Merck melanoma data at ESMO, which could shape sentiment toward cancer-focused biotechs. In the US, the Federal Reserve meets on October 27 and 28, with its decision due on Wednesday, October 28.